Amneal Pharmaceuticals, Inc. (AMRX) Stock Analysis
Amneal is shedding its legacy generic-drug valuation as complex generics, specialty brands, and the Kashiv biosimilar platform reshape it into a higher-margin biopharma compounder.
Overview
Amneal Pharmaceuticals is transitioning from a legacy generic manufacturer into a diversified, higher-margin biopharma platform focused on complex generics, biosimilars, and specialty branded medicines. FY2025 revenue reached $3.02B, led by Affordable Medicines, Specialty, and AvKARE. Growth is increasingly driven by complex injectables, biosimilars, government distribution, and proprietary neurology products such as Crexont. The company benefits from vertical integration, reliable supply, regulatory compliance, and formulation differentiation, though it remains heavily U.S.-centric and exposed to generic pricing and wholesaler concentration.